Abstract YO19
Case summary
Recent studies have shown evidence of cross-lineage transdifferentiation of B-cell lymphomas, such as low-grade FL and CLL/SLL,to histiocytic and dendritic cell sarcomas, but the clonal relationship between the 2 neoplasms is still unclear. Here, we report the morphologic, molecular and cytogenetic analysis of a unique case of CLL/SLL associated with indeterminate dendritic cell tumor and possibly a hybrid lymphodendritic cell neoplasm , using immunohistochemistry, electron microscopy, in situ hybridization and FISH.A 48-year-old Chinese female presented with left upper neck swelling. Blood examination revealed lymphocytosis.Microscopic examinations showed the lymph node has effaced architecture, and has a very complicated, variegated appearance with three distinct components. The first component contained small lymphocytes, prolymphocytes and paraimmunoblasts, showing typical CLL/SLL immunophenotype, with ZAP-70 positive and EBV negative. The second component contained nodular aggregates of large pink cells with abundant eosinophilic cytoplasm and deeply grooved nuclei, showing immunophenotype of indeterminate dendritic cell tumor and EBV positive. The third component had intermediate morphologic features between lymphoid cells and dendritic cells characteristics, a bit reminiscent of anaplastic large cell lymphoma, but expressed some B cell markers PAX5 and OCT2, as well as dendritic/histiocytic markers CD1a, CD68, Fascin, and Lysozyme, and was diffusely EBV positive. Electron microscopy revealed the cells in the third component had short and thick bulges like dendritic cell. FISH analysis using CLL probes showed identical deletion 17p13.1, deletion 11q22.3, and deletion 13q14.3 in all 3 components. Sharing of CD5 and OCT2 expression and identical cytogenetic abnormality in all 3 components suggest a common clonal origin for the three components.Our study provides evidence for transdifferentiation of CLL/SLL to dendritic cell tumor possibly via the intermediate linklymplymphodendritic cell neoplasm, and suggests that EBV may play a role in this phenomenon.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract